{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:19:09Z","timestamp":1792819149218,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07646-9","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:15:59Z","timestamp":1762751759000},"page":"2295-2303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual-tracer PET\/CT identifies an aggressive PSMA-negative\/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Ruohua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaochu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-3978","authenticated-orcid":false,"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"7646_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596\u2013604.","journal-title":"J Nucl Med"},{"key":"7646_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","volume":"36","author":"J Corfield","year":"2018","unstructured":"Corfield J, Perera M, Bolton D, Lawrentschuk N. (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36:519\u201327.","journal-title":"World J Urol"},{"key":"7646_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bju.13540","volume":"119","author":"PJ van Leeuwen","year":"2017","unstructured":"van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209\u201315.","journal-title":"BJU Int"},{"key":"7646_CR4","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1007\/s00261-023-04002-z","volume":"48","author":"S Houshmand","year":"2023","unstructured":"Houshmand S, Lawhn-Heath C, Behr S. PSMA PET imaging in the diagnosis and management of prostate cancer. Abdom Radiol. 2023;48:3610\u201323.","journal-title":"Abdom Radiol"},{"key":"7646_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","volume":"54","author":"DEK Sutherland","year":"2024","unstructured":"Sutherland DEK, Azad AA, Murphy DG, Eapen RS, Kostos L, Hofman MS. Role of FDG PET\/CT in management of patients with prostate cancer. Semin Nucl Med. 2024;54:4\u201313.","journal-title":"Semin Nucl Med"},{"key":"7646_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.262250","volume":"63","author":"R Chen","year":"2022","unstructured":"Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, et al. The added value of (18)F-FDG PET\/CT compared with (68)Ga-PSMA PET\/CT in patients with castration-resistant prostate cancer. J Nucl Med. 2022;63:69\u201375.","journal-title":"J Nucl Med"},{"key":"7646_CR7","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1007\/s00259-021-05221-6","volume":"48","author":"R Chen","year":"2021","unstructured":"Chen R, Wang Y, Shi Y, Zhu Y, Xu L, Huang G. Diagnostic value of 18F-FDG PET\/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:2970\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7646_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MNM.0000000000001371","volume":"42","author":"A Adnan","year":"2021","unstructured":"Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (\u201cPro-PET\u201d score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42:566\u201374.","journal-title":"Nucl Med Commun"},{"key":"7646_CR9","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","volume":"48","author":"K Michalski","year":"2021","unstructured":"Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, et al. Prognostic implications of dual tracer PET\/CT: PSMA ligand and [(18)F]FDG PET\/CT in patients undergoing [(177)Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48:2024\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7646_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378.","journal-title":"J Nucl Med"},{"key":"7646_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.juro.2017.06.085","volume":"198","author":"B Bhindi","year":"2017","unstructured":"Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, et al. Independent validation of the American Joint Committee on Cancer 8th edition prostate cancer staging classification. J Urol. 2017;198:1286\u201394.","journal-title":"J Urol"},{"key":"7646_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363.","journal-title":"JAMA Oncol"},{"key":"7646_CR13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969\u201374.","journal-title":"JAMA"},{"key":"7646_CR14","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2967\/jnumed.122.265368","volume":"64","author":"M Chen","year":"2023","unstructured":"Chen M, Fu Y, Peng S, Zang S, Ai S, Zhuang J, et al. The association between [(68)Ga]PSMA PET\/CT response and biochemical progression in patients with high-risk prostate cancer receiving neoadjuvant therapy. J Nucl Med. 2023;64:1550\u20135.","journal-title":"J Nucl Med"},{"key":"7646_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/fmch-2019-000262","volume":"8","author":"MZI Chowdhury","year":"2020","unstructured":"Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020;8:e000262.","journal-title":"Fam Med Community Health"},{"key":"7646_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.122.264104","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, et al. The prognostic value of posttreatment (68)Ga-PSMA-11 PET\/CT and (18)F-FDG PET\/CT in metastatic castration-resistant prostate cancer treated with (177)Lu-PSMA-617 and NOX66 in a phase I\/II trial (LuPIN). J Nucl Med. 2023;64:69\u201374.","journal-title":"J Nucl Med"},{"key":"7646_CR17","unstructured":"J.P. Buteau, A.J. Martin, L. Emmett, A. Iravani, S. Sandhu, A.M. Joshua, R.J. Francis, A.Y. Zhang, A.M. Scott, S.T. Lee, A.A. Azad, M.M. McJannett, M.R. Stockler, S.G. Williams, I.D. Davis, M.S. Hofman, P.T.I. Thera, A. the, U. New Zealand, G. (2022) Prostate Cancer Trials, PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial, Lancet Oncol, 23:1389\u20131397."},{"key":"7646_CR18","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7646_CR19","doi-asserted-by":"crossref","unstructured":"Y. Li, X. Gao, J. Yang, Y. Tang, S. Hu, (2025) PSMA-negative Widespread Metastases Identified by 18F-FDG PET\/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation, Clin Nucl Med.","DOI":"10.1097\/RLU.0000000000006106"},{"key":"7646_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41391-020-0202-x","volume":"23","author":"S Meziou","year":"2020","unstructured":"Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallee E, Bergeron M, et al. GLUT1 expression in high-risk prostate cancer: correlation with (18)F-FDG-PET\/CT and clinical outcome. Prostate Cancer Prostatic Dis. 2020;23:441\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7646_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683793","volume":"11","author":"K Shen","year":"2021","unstructured":"Shen K, Liu B, Zhou X, Ji Y, Chen L, Wang Q, et al. The evolving role of (18)F-FDG PET\/CT in diagnosis and prognosis prediction in progressive prostate cancer. Front Oncol. 2021;11:683793.","journal-title":"Front Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07646-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:36Z","timestamp":1771479516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07646-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7646"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07646-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants conforms to the principles of Renji hospital ethics committee and the declaration of Helsinki in 1964. Animal-based research was not included in the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No potential conflict of interest was reported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}